Mineralys Therapeutics, Inc. (MLYS) Stock Analysis
Healthcare · Biotechnology · NasdaqGS
Mineralys Therapeutics, Inc. (MLYS) posted $0 in revenue for fiscal 2025, with a net loss of $154.65M, per its SEC filings.
Data last refreshed August 2, 2026 from SEC filings · how we compute this
The analyst's take on Mineralys Therapeutics, Inc.
Mineralys Therapeutics, Inc. has grown revenue from $0 to $0 over the last 4 fiscal years.
The one thing worth a second look in the filings is share count rising (dilution).
Synthesised from Mineralys Therapeutics, Inc.'s SEC filings — descriptive, not advice. Ask the analyst your own question →
Mineralys Therapeutics, Inc. revenue & earnings — last 4 fiscal years
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| Gross profit | — | — | — | — |
| Net income | $-29.80M | $-71.90M | $-177.81M | $-154.65M |
| Net margin | — | — | — | — |
Source: Mineralys Therapeutics, Inc. SEC filings (10-K).
Mineralys Therapeutics, Inc.: 1 potential red flag in the filings
Patterns in the filed statements worth a second look — computed and cited, not AI guesswork, and not a signal to sell. The kind of thing that hides in a 10-K.
- Share count rising (dilution)Shares outstanding grew 108.8% over 3 years (39.1M → 81.5M) — existing holders' stakes are being diluted.
Explore 4 years of Mineralys Therapeutics, Inc. financials — interactive
Full income statement, balance sheet and cash flow with CAGR and trend on every row, 48 quarters, valuation ratios, plain-English health checks, and Ask — our SEC-grounded research assistant.
Open the interactive view — freeOr start a 7-day free trial to track MLYS in your portfolio →
Mineralys Therapeutics, Inc. financial history by metric
About Mineralys Therapeutics, Inc.
Mineralys Therapeutics, Inc., a biopharmaceutical company, develops medicines to target diseases driven by dysregulated aldosterone in the United States. It is developing lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by dysregulated aldosterone, such as hypertension, chronic kidney disease, and obstructive sleep apnea. The company was formerly known as Catalys SC1, Inc. and changed its name to Mineralys Therapeutics, Inc. in May 2020. Mineralys Therapeutics, Inc. was incorporated in 2019 and is headquartered in Radnor, Pennsylvania.
Mineralys Therapeutics, Inc. — frequently asked questions
What is Mineralys Therapeutics, Inc.'s revenue?
Mineralys Therapeutics, Inc. (MLYS) reported revenue of $0 for fiscal year 2025, according to its SEC filings.
Is Mineralys Therapeutics, Inc. profitable?
No — MLYS reported a net loss of $-154.65M in fiscal 2025.
What is MLYS's P/E ratio?
Mineralys Therapeutics, Inc. trades at a price-to-earnings ratio of about 0.0 based on the latest data in our nightly-refreshed cache.
How much debt does Mineralys Therapeutics, Inc. have?
As of fiscal year 2025, MLYS carried roughly $0 in total debt (short- plus long-term borrowings), per its filed balance sheet.
What is Mineralys Therapeutics, Inc.'s market cap?
Mineralys Therapeutics, Inc. (MLYS) has a market capitalization of about $2.09B, based on the latest data in our nightly-refreshed cache.
When does Mineralys Therapeutics, Inc.'s fiscal year end?
MLYS's fiscal year ends in December. Its most recent annual filing covers the fiscal year ending 2025-12-31.
Where does this data come from?
All figures are computed from Mineralys Therapeutics, Inc.'s official SEC filings (10-K and 10-Q), covering 4 years of history, refreshed nightly. stockportfolio.pro does not provide investment advice.